Infertility-related stress and the risk of antidepressants prescription in women: a 10-year register study.

STUDY QUESTION: Is the first-time redeemed prescription of antidepressants predicted by the level of infertility-related stress in women seeking ART treatment? SUMMARY ANSWER: Infertility-related stress in the personal and marital domains and general physical stress reactions were significant predictors of a first redeemed prescription of antidepressants after ART treatment in this 10-year follow-up cohort study. WHAT IS KNOWN ALREADY: The literature has found inconsistent findings regarding the association between infertility-related stress and later psychological adjustment in fertility patients. The association between infertility-related stress and later prescription of antidepressants had never been explored in long-term cohort studies. STUDY DESIGN, SIZE, DURATION: All women (n = 1169) who participated in the Copenhagen Cohort Multi-centre Psychosocial Infertility (COMPI) cohort study in the year 2000 (questionnaire data) were linked with the register-based Danish National ART-Couple (DANAC) I cohort, which includes women and their partners having received ART treatment from 1 January 1994 to 30 September 2009. The study population were among other national health and sociodemographic registers further linked with the Danish National Prescription Registry. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women initiating ART treatment were followed until they had redeemed the first prescription of antidepressants or until 31 December 2009. Logistic regression analyses were conducted to test the association between general physical stress reactions and infertility-related stress in the personal, marital and social domains, respectively, and a future redeemed prescription of antidepressants. Age, education level, marital status, number of fertility treatments prior to study inclusion and female infertility diagnosis were included as covariates in the adjusted analyses. Further, the analysis was stratified according to childbirth or no childbirth during follow-up. MAIN RESULTS AND THE ROLE OF CHANCE: The final sample consisted of 1009 women with a mean age of 31.8 years. At study inclusion, women had tried to conceive for an average of 3.45 years. At 10-year follow-up, a total of 13.7% of women had a first redeemed prescription of antidepressant medication. The adjusted odds ratio (OR) showed that high general physical stress predicted the later prescription of antidepressants (adjusted (adj) OR = 2.85, 95% confidence interval (CI) 1.96-4.16). Regarding infertility-related stress domains, high personal stress (adj OR = 2.14, 95% CI 1.46-3.13) and high marital stress (adj OR = 1.80, 95% CI 1.23-2.64) were significantly associated with the later prescription of antidepressants. Social stress was not significantly associated with the future redeemed prescription of antidepressants (adj OR = 1.10, 95% CI 0.76-1.61). Among women not having achieved childbirth during follow-up, the risk of a first-time prescription of antidepressants associated with infertility-specific stress was higher compared to the risk among women having childbirth during follow-up. LIMITATIONS, REASONS FOR CAUTION: This study did not account for potential mediating factors, such as negative life events, which could be associated with the prescription of antidepressants. Second, we are not able to know if these women had sought psychological support during follow-up. Additionally, antidepressants might be prescribed for other health conditions than depressive disorders. WIDER IMPLICATIONS OF THE FINDINGS: Our results suggest that women presenting high infertility-related stress in the personal and marital domains were at higher risk of redeemed first-time prescription of antidepressants after ART, independently of having delivered a child or not after initiation of ART treatment. Women would benefit from an initial screening specifically for high infertility-related stress. The COMPI Fertility Problem Stress Scales can be used by clinical staff in order to identify women in need of psychological support before starting ART treatments. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the Portuguese Foundation for Science and Technology (FCT) under an individual doctoral grant attributed to the first author (SFRH/BD/103234/2014). The establishment of the DANAC I cohort was funded by Rosa Ebba Hansen's Fund. The COMPI Infertility Cohort project was supported by The Danish Health Insurance Fund (J.nr. 11/097-97), the Else and Mogens Wedell-Wedellsborgs Fund, the manager E. Danielsens and Wife's Fund, the merchant L.F. Foghts Fund, the Jacob Madsen and Wife Olga Madsens Fund. The authors have no conflicts of interest. TRIAL REGISTRATION NUMBER: NA.

Involvement of the nitric oxide pathway in the anti-depressant-like effects of thalidomide in mice.

BACKGROUND: Thalidomide is a sedative/hypnotic agent that is currently used to treat patients suffering from multiple myeloma, myelodysplastic syndromes and erythema nodosum leprosum. Although previous studies have demonstrated that thalidomide possesses anti-depressant-like properties, the exact mechanism that thalidomide exerts this effect is not understood. In this study, we used two mouse models of depression and investigated the possible role of nitric oxide (NO), NO synthase (NOS) and inducible NOS (iNOS) in the ant-depressant-like effects of thalidomide. METHODS: Male mice were injected with different doses of thalidomide intraperitoneally. In order to assess the anti-depressant-like properties of thalidomide, the immobility time of mice was assessed in the forced swimming test (FST) and tail suspension test (TST). Locomotor activity was assessed using the open-field test. To assess the role of nitric oxide, N(G)-nitro-L-arginine methyl ester (L-NAME, non-specific NOS inhibitor), aminoguanidine (selective iNOS inhibitor) or L-arginine (NO precursor) were administered intraperitoneally along with specific doses of thalidomide. RESULTS: Thalidomide (10 mg/kg) significantly reduced immobility time in FST and TST. Aminoguanidine (50 mg/kg) and L-NAME (10 mg/kg) significantly augmented the anti-immobility effects of thalidomide (5 mg/kg). L-arginine (750 mg/kg) significantly inhibited the anti-immobility effects of thalidomide (10 mg/kg). None of the treatment groups demonstrated alteration of locomotor activity. CONCLUSION: Thalidomide exerts its anti-depressant-like effects through a mechanism dependent upon NO inhibition.

Antidepressants plus benzodiazepines for adults with major depression.

BACKGROUND: Anxiety frequently coexists with depression and adding benzodiazepines to antidepressant treatment is common practice to treat people with major depression. However, more evidence is needed to determine whether this combined treatment is more effective and not any more harmful than antidepressants alone. It has been suggested that benzodiazepines may lose their efficacy with long-term administration and their chronic use carries risks of dependence.This is the 2019 updated version of a Cochrane Review first published in 2001, and previously updated in 2005. This update follows a new protocol to conform with the most recent Cochrane methodology guidelines, with the inclusion of 'Summary of findings' tables and GRADE evaluations for quality of evidence. OBJECTIVES: To assess the effects of combining antidepressants with benzodiazepines compared with antidepressants alone for major depression in adults. SEARCH METHODS: We searched the Cochrane Common Mental Disorders Group's Controlled Trials Register (CCMDCTR), the Cochrane Central Register of Controlled Trials, MEDLINE, Embase and PsycINFO to May 2019. We searched the World Health Organization (WHO) trials portal and ClinicalTrials.gov to identify any additional unpublished or ongoing studies. SELECTION CRITERIA: All randomised controlled trials that compared combined antidepressant plus benzodiazepine treatment with antidepressants alone for adults with major depression. We excluded studies administering psychosocial therapies targeted at depression and anxiety disorders concurrently. Antidepressants had to be prescribed, on average, at or above the minimum effective dose as presented by Hansen 2009 or according to the North American or European regulations. The combination therapy had to last at least four weeks. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data and assessed risk of bias in the included studies, according to the criteria of the Cochrane Handbook for Systematic Reviews of Interventions. We entered data into Review Manager 5. We used intention-to-treat data. We combined continuous outcome variables of depressive and anxiety severity using standardised mean differences (SMD) with 95% confidence intervals (CIs). For dichotomous efficacy outcomes, we calculated the risk ratio (RR) with 95% CI. Regarding the primary outcome of acceptability, only overall dropout rates were available for all studies. MAIN RESULTS: We identified 10 studies published between 1978 to 2002 involving 731 participants. Six studies used tricyclic antidepressants (TCAs), two studies used selective serotonin reuptake inhibitors (SSRIs), one study used another heterocyclic antidepressant and one study used TCA or heterocyclic antidepressant.Combined therapy of benzodiazepines plus antidepressants was more effective than antidepressants alone for depressive severity in the early phase (four weeks) (SMD -0.25, 95% CI -0.46 to -0.03; 10 studies, 598 participants; moderate-quality evidence), but there was no difference between treatments in the acute phase (five to 12 weeks) (SMD -0.18, 95% CI -0.40 to 0.03; 7 studies, 347 participants; low-quality evidence) or in the continuous phase (more than 12 weeks) (SMD -0.21, 95% CI -0.76 to 0.35; 1 study, 50 participants; low-quality evidence). For acceptability of treatment, there was no difference in the dropouts due to any reason between combined therapy and antidepressants alone (RR 0.76, 95% CI 0.54 to 1.07; 10 studies, 731 participants; moderate-quality evidence).For response in depression, combined therapy was more effective than antidepressants alone in the early phase (RR 1.34, 95% CI 1.13 to 1.58; 10 studies, 731 participants), but there was no evidence of a difference in the acute phase (RR 1.12, 95% CI 0.93 to 1.35; 7 studies, 383 participants) or in the continuous phase (RR 0.97, 95% CI 0.73 to 1.29; 1 study, 52 participants). For remission in depression, combined therapy was more effective than antidepressants alone in the early phase (RR 1.39, 95% CI 1.03 to 1.90, 10 studies, 731 participants), but there was no evidence of a difference in the acute phase (RR 1.27, 95% CI 0.99 to 1.63; 7 studies, 383 participants) or in the continuous phase (RR 1.31, 95% CI 0.80 to 2.16; 1 study, 52 participants). There was no evidence of a difference between combined therapy and antidepressants alone for anxiety severity in the early phase (SMD -0.76, 95% CI -1.67 to 0.14; 3 studies, 129 participants) or in the acute phase (SMD -0.48, 95% CI -1.06 to 0.10; 3 studies, 129 participants). No studies measured severity of insomnia. In terms of adverse effects, the dropout rates due to adverse events were lower for combined therapy than for antidepressants alone (RR 0.54, 95% CI 0.32 to 0.90; 10 studies, 731 participants; moderate-quality evidence). However, participants in the combined therapy group reported at least one adverse effect more often than participants who received antidepressants alone (RR 1.12, 95% CI 1.01 to 1.23; 7 studies, 510 participants; moderate-quality evidence).Most domains of risk of bias in the majority of the included studies were unclear. Random sequence generation, allocation concealment, blinding and selective outcome reporting were problematic due to insufficient details reported in most of the included studies and lack of availability of the study protocols. The greatest limitation in the quality of evidence was issues with attrition. AUTHORS' CONCLUSIONS: Combined antidepressant plus benzodiazepine therapy was more effective than antidepressants alone in improving depression severity, response in depression and remission in depression in the early phase. However, these effects were not maintained in the acute or the continuous phase. Combined therapy resulted in fewer dropouts due to adverse events than antidepressants alone, but combined therapy was associated with a greater proportion of participants reporting at least one adverse effect.The moderate quality evidence of benefits of adding a benzodiazepine to an antidepressant in the early phase must be balanced judiciously against possible harms and consideration given to other alternative treatment strategies when antidepressant monotherapy may be considered inadequate. We need long-term, pragmatic randomised controlled trials to compare combination therapy against the monotherapy of antidepressant in major depression.

Conversion disorder: "an adverse reaction" to watch out for.

A subject was enrolled in a multicenter, double-blinded clinical trial of ofloxacin-containing multidrug therapy for leprosy by the World Health Organization in 1992 and she developed multiple physical symptoms a few hours after taking the regimen. Physical examination and laboratory work-ups could not support a medical diagnosis and she was eventually dropped from the study. Decoding revealed that she belonged in the control group given the World Health Organization/multiple drug therapy-multibacillary regimen. In the course of treatment, she was diagnosed with conversion disorder and was subsequently treated with an antipsychotic.

Efeito dos anticonvulsivantes gabapentina e carbamazepina associados ou não ao antidepressivo amitriptilina no controle da dor neuropática em pacientes portadores de Hanseníase / The effects of the antiepiletic drugs gabapentin, carbamazepine, either used in association with amitriptyline or not, in the control of neuropathic pain in Hansen disease patients

Este é um estudo clínico, prospectivo, aleatório, e duplamente encoberto realizado em 80 doentes hansênicos de ambos os sexos e com idade variando entre 18 e 65 anos, portadores de dor neuropática. Os pacientes foram divididos em 4 grupos: Grupo G: pacientes tratados com gabapentina na dose de 400mg diários, Grupo C: pacientes tratados com carbamazepina na dose de 200 mg diários, Grupo GA: pacientes tratados com a associação de gabapentina 400 mg e amitriptilina 25 mg diários e Grupo CA: pacientes tratados com a associação de carbamazepina 200 mg e amitriptilina 25 mg diários e avaliados durante 4 meses quanto a intensidade da dor, consumo de prednisona, necessidade do uso de talidomida, queixa de queimação, parestesia, sensação de choque e alteração da sensibilidade, bem como da necessidade de realização de neurólise e eventos adversos relacionados ao tratamento. Os resultados permitiram verificar que o valor médio de intensidade de dor foi semelhante em todos os grupos no momento da inclusão e no momento de encerramento do estudo, e a diminuição da dor foi semelhante em todos os grupos, não havendo superioridade de nenhum dos esquemas terapêuticos sobre o outro, portanto a carbamazepina isolada ou associada a amitriptilina e a gabapentina isolada ou associada a amitriptilina foram igualmente eficientes na redução da dor que os pacientes apresentavam no momento de inclusão no estudo, porém a duração da dor, em dias, foi maior no grupo medicado com a gabapentina isolada, foi menor e igual nos grupos medicados com a carbamazepina e com a gabapentina associada a amitriptilina e teve uma duração intermediária no grupo medicado com a carbamazepina associada a amitriptilina, embora a diferença não tenha sido significativa pela análise estatística. Todos os fármacos foram igualmente eficazes na redução do consumo da prednisona e na necessidade do uso de talidomida. A queixa de queimação, de parestesia, de sensação de choque e de alteração da sensibilidade...

This study is a clinical trial. During the present study a prospective controlled four-way crossover double-blind randomized protocol was followed. Eighty hansen's patients, male and female, aged 18 to 65, with neuropathic pain took part. The patients were divided into 4 groups as follows: Group G -patients treated with a gabapentin 400 mg dose daily; Group C - patients treated with a carbamazepine 200 mg dose daily; Group GA - patients treated with a gabapentin 400 mg dose in association with an amitriptyline 25 mg daily, Group CA - patients treated with a carbamazepine 200 mg dose in association with an amitriptyline 25 mg daily. All four groups were assessed for four months taking into account pain intensity, prednisone consumption, the amount of thalidomide needed, burn sensation complaints, paresthesia, numbness, shock sensitivity and alterations to sensitivity, as well as neurolysis and side effects related to the treatment. The results of the study demonstrated that intensity of pain was similar in patients belonging to all four groups, both at the moment of inclusion and at the end of the study, and the reduction in the intensity of pain was also similar in all groups, without any report of superior effectiveness in any of the four groups studied. Therefore, the gabapentin and the carbamazepine, alone or in association with amitriptyline, proved to be equally effective in the reduction of the pain the patients felt at the moment of their inclusion to the present study. On the other hand, during the assessment of the duration of pain in days we noticed that it lasted longer in the group treated only with gabapentin, it was shorter or the same in the groups treated with carbamazepine and with gabapentin in association with an amitriptyline, and was considered intermediary in the group treated with carbamazepine in association with an amitriptyline, even though the difference was not considered significant in terms of statistical analysis...

Efeito dos anticonvulsivantes gabapentina e carbamazepina associados ou não ao antidepressivo amitriptilina no controle da dor neuropática em pacientes portadores de hanseníase / The effects of the antiepiletic drugs gabapentin, carbamazepine, either used in association with amitriptyline or not, in the control of neuropathic pain in Hansen's disease patients

Estudo clínico, prospectivo, aleatório, duplamente encoberto em 80 hansênicos com dor neuropática, de ambos sexos, idade entre 18 e 65 anos, divididos em 4 grupos: gabapentina 400mg/dia, carbamazepina 200/mg dia, gabapentina 400mg/dia e amitriptilina 25 mg/dia, carbamazepina 200 mg/dia e amitriptilina 25 mg/dia, avaliados por 4 meses quanto intensidade e duração da dor. A intensidade da dor foi semelhante em todos os grupos no momento da inclusão e encerramento do estudo, a diminuição da dor foi semelhante em todos os grupos, não havendo superioridade de nenhuma das terapêuticas. Duração da dor, em dias, foi maior no grupo gabapentina, foi menor e igual nos grupos carbamazepina e gabapentina/amitriptilina e intermediária no grupo carbamazepina/amitriptilina / This study is a clinical trial prospective controlled four-way crossover double-blind randomized. Eighty Hansen's patients, male and female, aged 18 to 65, with neuropathic pain took part. The patients were divided into 4 groups as follows: gabapentin 400 mg dose daily, carbamazepine 200 mg dose daily, gabapentin 400 mg dose in association with an amitriptyline 25 mg daily, carbamazepine 200 mg dose in association with an amitriptyline 25 mg daily, assessed for four months taking into account pain intensity.The results demonstrated that intensity of pain was similar in patients belonging to all groups,at the moment of inclusion and at the end of the study. The reduction in the intensity of pain was also similar in all groups, without any report of superior effectiveness in any of the four groups studied...

Neuropathic pain in leprosy.

Chronic neuropathic pain in treated leprosy has received scant attention. In this article the concept, clinical features and diagnosis of neuropathic pain are reviewed. The possible pathophysiological mechanisms, treatment challenges and research needs in this area are discussed.

Temas de farmacología

Recopilación de temas de la cátedra de Farmacología de la Facultad de Medicina de la UNNE

Temas de farmacología

Recopilación de temas de la cátedra de Farmacología de la Facultad de Medicina de la UNNE